ADC TOXICITY ATLAS
← Atlas

AB-160

Investigational
AB 160; AB160; nab-paclitaxel/bevacizumab complex; nab-paclitaxel/bevacizumab 160-nm nano-immunoconjugate
Sponsor
Mayo Clinic
Indication
Recurrent/metastatic gynecologic cancer (endometrial, platinum-resistant ovarian, cervical)
Target family
Other
RP2D dose
nab-paclitaxel 150 mg/m2 + bevacizumab 60 mg/m2 (DL2)
Days 1, 8, 15 of 28-day cyclePooled
01
Multi-organ toxicity

Fingerprint & organ drill-down

Also reported
0%severity100%
0
Assessed · clear
true 0%
No data
never assessed
3 adverse-event terms

Ocular

Any-grade
10%
G3+
0%
Pooled
sagittal schematic · -

Tissues shaded by reported adverse-event rate.

Cornea
AE
-
Express.
-
Limbus
AE
-
Express.
-
Conjunctiva
AE
-
Express.
-
Lens
AE
-
Express.
-
Retina / RPE
AE
-
Express.
-
Dominant tissue
Mixed
Surface subtype
Mixed
Reversibility
-
Reported ocular events
Blurred vision10%
n=10
Dry eye10%
n=10
Watering eyes (epiphora / lacrimation increased)10%
n=10
Per-trial detail

Adverse events by trial

AB160 Phase I (NCT02020707)Phase 1AB160: ABX 125-175 mg/m2 + BEV 50-70 mg/m2 (DL1-DL3) IV days 1, 8, 15 of 28-day cyclen=10CTCAE 4.0PooledCto verify
Kalogera E et al, Clin Cancer Res 2024;30(12):2623-2635 | any-grade derived = sum of mutually-exclusive worst-grade cells PMID:38530846; PMC11176914; DOI:10.1158/1078-0432.CCR-23-3196
48 adverse-event terms · 1 system · expand a system below
Other48
Anemia
100%G3+ 10%
10/10
Fatigue
100%G3+ 10%
10/10
Nausea
100%
10/10
WBC decrease
100%G3+ 30%
10/10
Neutrophil count decrease
90%G3+ 50%
9/10
Peripheral sensory neuropathy
90%
9/10
Alopecia
80%
8/10
Diarrhea
80%
8/10
Hypertension
80%
8/10
Abdominal pain
60%G3+ 10%
6/10
Arthralgia
60%
6/10
Myalgia
60%
6/10
Epistaxis
50%
5/10
Lymphocyte count decrease
50%G3+ 20%
5/10
Vomiting
50%
5/10
Anorexia
40%
4/10
Alkaline phosphatase increase
30%
3/10
Platelet count decrease
30%
3/10
Allergic reaction
20%
2/10
Constipation
20%
2/10
Gastrointestinal disorders, other
20%
2/10
General disorder and administrative site conditions, other
20%
2/10
Limb edema
20%
2/10
Maculo-papular rash
20%
2/10
Peripheral motor neuropathy
20%
2/10
Proteinuria
20%
2/10
Thromboembolic event
20%G3+ 10%
2/10
Aspiration
10%G3+ 10%
1/10
Blurred vision
10%
1/10
Cough
10%
1/10
Dehydration
10%
1/10
Dry eye
10%
1/10
Dysgeusia
10%
1/10
Fever
10%
1/10
Hyponatremia
10%
1/10
Leukocytosis
10%G3+ 10%
1/10
Malaise
10%
1/10
Muscle weakness lower limb
10%G3+ 10%
1/10
Nail discoloration
10%
1/10
Neck pain
10%
1/10
Pain in extremity
10%
1/10
Papulopustular rash
10%
1/10
Pruritus
10%
1/10
Pustular rash
10%
1/10
Vaginal hemorrhage
10%
1/10
Weight gain
10%
1/10
Weight loss
10%
1/10
Watering eyes
10%
1/10
02
Construct

Molecular anatomy

Antibody
IgG1
Humanized
Linker
N/A
Undisclosed (ADCdb); not a covalent-ADC DAR — AB-160 is a non-covalent nab-paclitaxel/bevacizumab nanoparticle complex, so a conventional drug-to-antibody ratio is not defined
DAR
Payload
Microtubule stabilizer / tubulin inhibitor (antimitotic)
Linker structure
structure not applicable
Payload structureC47H51NO14
CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C
03
Antibody

Antibody & Fc engineering

Antibody
Bevacizumab
Isotype
IgG1
Origin
Humanized
Fc modifications
None
Glycoengineering
Standard
Effector silencing
None (wild-type bevacizumab IgG1 Fc; mechanism is VEGF-A ligand neutralization, not Fc effector function)
FcγR binding
Retained
C1q binding
Retained
Target KD (nM)
795
Epitope / domain
Bevacizumab Fab CDR-H3 loop binds HSA Peptide 40
04
Linker & conjugation

Linker chemistry

Linker profile
Linker
None (non-covalent nanoparticle coating)
Class
Non-covalent
Cleavage
N/A
Attachment
Non-covalent
Conjugation
Non-covalent: bevacizumab adsorbed onto albumin-bound (nab) paclitaxel forming a ~160 nm nano-immunoconjugate
Symmetry
-
DAR (mean)
Undisclosed (ADCdb); not a covalent-ADC DAR — AB-160 is a non-covalent nab-paclitaxel/bevacizumab nanoparticle complex, so a conventional drug-to-antibody ratio is not defined
DAR homogeneity
-
Plasma t½
1 d
Cleavage trigger
-
Release control
N/A
Hydrophilicity mask
N/A
Platform
nab-particle non-covalent antibody coating
Formula
-
Linker MW
-
Linker TPSA
-
Linker xLogP
-
ADCdb linker
-
In-vitro stability
-
05
Payload

Payload & physicochemistry

Payload profile
Payload
Paclitaxel
Class
Taxane
Mechanism
Microtubule stabilizer / tubulin inhibitor (antimitotic)
Released catabolite
Paclitaxel (free taxane; delivered as albumin-bound nab-paclitaxel)
Mechanistic subtype
Tubulin-other
Stereochem / salt
Paclitaxel free base (natural taxane stereochemistry)
Bystander
-
PAMPA rank
-
MW
853.9 Da
XLogP3
2.5
logD₇.₄
-
TPSA
221 Ų
pKa
-
Charge pH 7.4
0
H-bond donors
4
H-bond acceptors
14
IC50 (HCEC)
-
Formula
C47H51NO14
PubChem CID
36314
ADCdb payload
PAY0VUPQZ
Bioactivity note
Payload paclitaxel: microtubule-stabilizing taxane (binds beta-tubulin, blocks microtubule depolymerization; ADCdb therapeutic target Microtubule PATR0CXRBX). Bevacizumab binds/neutralizes VEGF-A. No discrete IC50/binding affinity values reported on the ADCdb AB-160 page. Phase I
06
Dosing & regimen

Dosing

RP2D dose
nab-paclitaxel 150 mg/m2 + bevacizumab 60 mg/m2 (DL2)
Schedule
Days 1, 8, 15 of 28-day cycle
Route
IV
Fractionated
No
n at RP2D
21
Dose basis
BSA
Trial phase
Phase 1
Dose-OAE available
No
Tox summary basis
dose-escalation
08
Ocular & expression

Ocular profile & eye-tissue target expression

Target profile
OAE any-grade
10 %
OAE grade 3+
0 %
OAE data status
reported
Severity (weighted)
3
Keratopathy
-
Conjunctival
-
Dry eye
10 %
Blurred vision
10 %
Dominant tissue
Mixed
Surface subtype
Mixed
Grading scale
CTCAE v4.0
Reversibility
-
Target expression in eye tissues (HCA detection · HPA bulk)
Cornea (central)
-
Cornea (limbal)
-
Conjunctiva
-
RPE
-
Retina (HPA)
-
Cross-trial comparability · source-verified
Ascertainment: Symptom-driven reportingScale: CTCAE v4Denominator: RP2D
Ocular AE grading reference — interspecialty consensus · 6 scales + dose modification
09
Identity & registry

Identifiers, registry & notes

ADC id
ab-160
Approval status
Investigational
Approval year
-
UniProt
P15692
ADCdb ADC
DRG0IRZPG
ADCdb antibody
ANI0IZQGT
ADCdb target
TAR0VKDND
Primary source
Kalogera et al., Clin Cancer Res 2024;30(12):2623 (PMID 38530846; PMC11176914; NCT02020707/MC1371), Table 3
Aliases & development codes
AB 160; AB160; nab-paclitaxel/bevacizumab complex; nab-paclitaxel/bevacizumab 160-nm nano-immunoconjugate
Notes
CRITICAL CLASS CAVEAT: AB-160 (AB160) is NOT a classic covalent ADC. It is a ~160 nm nano-immunoconjugate in which nab-paclitaxel (albumin-bound paclitaxel) nanoparticles are NON-COVALENTLY coated with bevacizumab to target VEGF-A-rich tissue. Consequently there is no chemical linker, no DAR, and no conjugation site (ADCdb lists linker and DAR as 'Undisclosed'; mechanistically they are non-covalent/non-applicable). The "target" (VEGF-A) is a soluble secreted ligand, not a cell-surface antigen. ADCdb cross-refs: DRG0IRZPG, antibody ANI0IZQGT (bevacizumab), target TAR0VKDND (VEGFA), payload PAY0VUPQZ (paclitaxel). Sponsor: Mayo Clinic (investigator-initiated). TRIAL/OAE STRUCTURE: Phase I NCT02020707 (MC1371), CTCAE v4.0. Total evaluable safety N=21 across THREE cohorts: (1) gynecologic dose-escalation cohort N=10 spanning DL1-DL3 (protocol-allowed ABX 75-175 / BEV 30-70 mg/m2; three DLs tested 125/150/175 ABX); (2) endometrial-expansion N=6 at RP2D/DL2; (3) ovarian-expansion N=5 at RP2D/DL2. RP2D = DL2 (nab-paclitaxel 150 mg/m2 + bevacizumab 60 mg/m2), IV days 1/8/15 q28d; no DLTs. n_rp2d recorded as 21 (total safety-analysis denominator); the RP2D (DL2) disease-specific expansion cohorts total 11 (endometrial 6 + ovarian 5), plus unspecified DL2 escalation patients. OCULAR (qualifying data): Table 3 ("Grade 2-5 AEs regardless of attribution," which also tabulates the G1 column) lists THREE Grade-1 eye events, EACH at 10% (1/10), ALL confined to the dose-escalation cohort (N=10) and ABSENT from the RP2D endometrial/ovarian expansion cohorts: blurred vision 10%, dry eye 10%, and watering eyes/epiphora 10% (the screen hint missed the third PT). No Grade >=2 ocular event in any cohort -> oae_g3plus_pct=0 (documented). oae_any_pct reported as 10.0 (max across PTs per convention); patient overlap among the 3 ocular PTs is not resolvable, so the true any-ocular incidence is 10-30%. ocular_surface_subtype=Mixed (dry eye + epiphora = ocular surface/lacrimal; blurred vision = visual). Because OAE occurs only in the escalation cohort, ocular rows are tagged line_context to that cohort (N=10), NOT 'RP2D'. Reversibility not reported. These are taxane (free paclitaxel) class effects, NOT auristatin/maytansinoid corneal toxicity. DOMINANT TOXICITIES (context): hematologic - neutropenia and leukopenia/WBC decrease are the defining Grade 3/4 events (G3+ 50-83% across cohorts; abstract explicitly names neutropenia + leukopenia), anemia universal (100% any-grade, G3 10%). Thromboembolic events were also named as Grade 3/4 in the abstract (Table 3: G3 10% in escalation cohort) but are not captured in toxicity_rows because the organ_system enum has no vascular category. Note: the "44.4% neutropenia / 22.2% leukopenia" figures circulating in secondary summaries are NOT in the primary paper and were not used; per-cohort Table 3 values are reported instead. PHYSCHEM: paclitaxel = PubChem CID 36314 (MW 853.9; XLogP3 2.5; TPSA 221; formula C47H51NO14; neutral, charge 0). payload_bystander left blank (concept N/A for a non-covalent nanoparticle delivering free paclitaxel). Antibody isotype/origin/Fc (humanized IgG1, wild-type Fc, standard glycosylation) inferred from established bevacizumab identity = tier C. OTHER: AB160 was also studied in metastatic melanoma under the same MC1371/NCT02020707 program (JCO 2020;38(15_suppl):e22020); the OAE/toxicity data here are from the gynecologic Phase I publication (Kalogera et al., Clin Cancer Res 2024;30(12):2623). First author Eleftheria Kalogera.